CM
DNTH icon

Caption Management’s Dianthus Therapeutics DNTH Stock Holding History

Caption Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-138,561
Closed -$5.45M – 1686
2025
Q3 		$5.45M Buy
+138,561
New +$3.54M 0.04% 464

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caption Management's DNTH Position: Q4 2025 in Review

Caption Management sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 138,561 shares — an estimated $5.45M sold.

Caption Management first reported a position in DNTH in Q3 2025 and held it in 1 quarter. The position peaked at $5.45M in Q3 2025. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

  • Caption Management reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 138,561 Dianthus Therapeutics shares in Q4 2025, an estimated $5.45M.
  • Caption Management first reported a position in Dianthus Therapeutics in Q3 2025 and held it in 1 quarter.
  • Caption Management's Dianthus Therapeutics position peaked at $5.45M in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.